EP1165146A4 - Composes chelates metalliques radioactifs liposolubles destines au traitement de tumeurs - Google Patents

Composes chelates metalliques radioactifs liposolubles destines au traitement de tumeurs

Info

Publication number
EP1165146A4
EP1165146A4 EP00921373A EP00921373A EP1165146A4 EP 1165146 A4 EP1165146 A4 EP 1165146A4 EP 00921373 A EP00921373 A EP 00921373A EP 00921373 A EP00921373 A EP 00921373A EP 1165146 A4 EP1165146 A4 EP 1165146A4
Authority
EP
European Patent Office
Prior art keywords
tumor therapy
radioactive metal
metal chelates
lipid soluble
soluble radioactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00921373A
Other languages
German (de)
English (en)
Other versions
EP1165146A1 (fr
Inventor
Madhukar Mathew L Thakur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP1165146A1 publication Critical patent/EP1165146A1/fr
Publication of EP1165146A4 publication Critical patent/EP1165146A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00921373A 1999-03-09 2000-03-09 Composes chelates metalliques radioactifs liposolubles destines au traitement de tumeurs Withdrawn EP1165146A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12348399P 1999-03-09 1999-03-09
US123483P 1999-03-09
PCT/US2000/006207 WO2000053234A1 (fr) 1999-03-09 2000-03-09 Composes chelates metalliques radioactifs liposolubles destines au traitement de tumeurs

Publications (2)

Publication Number Publication Date
EP1165146A1 EP1165146A1 (fr) 2002-01-02
EP1165146A4 true EP1165146A4 (fr) 2003-09-17

Family

ID=22408928

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00921373A Withdrawn EP1165146A4 (fr) 1999-03-09 2000-03-09 Composes chelates metalliques radioactifs liposolubles destines au traitement de tumeurs

Country Status (4)

Country Link
EP (1) EP1165146A4 (fr)
JP (1) JP2002538225A (fr)
CA (1) CA2366593A1 (fr)
WO (1) WO2000053234A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4176300A (en) * 1999-04-02 2000-10-23 Ut-Battelle, Llc Indium-114m as a source for brachytherapy and related compositions and methods
WO2019243419A1 (fr) * 2018-06-19 2019-12-26 Danmarks Tekniske Universitet Gel de curiethérapie pour le traitement du cancer et/ou pour le guidage d'une intervention chirurgicale

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225409A1 (fr) * 1985-12-02 1987-06-16 The Dow Chemical Company Complexes d'acide organoaminophosphonique pour le traitement de tumeurs calciques
US4925925A (en) * 1988-06-15 1990-05-15 University Of Cincinnati Radioactive rhenium ligated to 2-hydroxy isobutyric acid and method of use
US5192526A (en) * 1989-05-02 1993-03-09 Mallinckrodt Medical, Inc. Kit for preparation of rhenium therapeutic agents for bone cancer without purification
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
DE19632052A1 (de) * 1996-08-08 1998-02-12 Michael Prof Dr Eisenhut Benzamidderivate und deren Verwendung zur Diagnose und Behandlung von Tumoren, insbesondere Melanomen
US5840859A (en) * 1995-07-06 1998-11-24 Research Corporation Technologies, Inc. (Aminostyryl)pyridinium compounds for radiolabelling cell membranes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017596A (en) * 1975-03-03 1977-04-12 Research Corporation Radiopharmaceutical chelates and method of external imaging
US5130118A (en) * 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225409A1 (fr) * 1985-12-02 1987-06-16 The Dow Chemical Company Complexes d'acide organoaminophosphonique pour le traitement de tumeurs calciques
US4925925A (en) * 1988-06-15 1990-05-15 University Of Cincinnati Radioactive rhenium ligated to 2-hydroxy isobutyric acid and method of use
US5192526A (en) * 1989-05-02 1993-03-09 Mallinckrodt Medical, Inc. Kit for preparation of rhenium therapeutic agents for bone cancer without purification
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5840859A (en) * 1995-07-06 1998-11-24 Research Corporation Technologies, Inc. (Aminostyryl)pyridinium compounds for radiolabelling cell membranes
DE19632052A1 (de) * 1996-08-08 1998-02-12 Michael Prof Dr Eisenhut Benzamidderivate und deren Verwendung zur Diagnose und Behandlung von Tumoren, insbesondere Melanomen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERNARD B F ET AL: "Tc-MIBI, Tc-Tetrofosmin and Tc-Q12 In Vitro and In Vivo - Human distribution, dosimetry, safety and preliminary comparison to thallium 201 for myocardial perfusion imaging", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 25, no. 3, 1 April 1998 (1998-04-01), pages 233 - 240, XP004113280, ISSN: 0969-8051 *
DEWANJEE M K ET AL: "TECHNETIUM-99M-LABELED PLATELETS: COMPARISON OF LABELING WITH A NEWLIPID-SOLUBLE SN(II)-MERCAPTOPYRIDINE-N-OXIDE AND 99M TC-HMPAO", INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION PART B: NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 18, no. 5, 1991, pages 461 - 468, XP000827908, ISSN: 0883-2897 *
KOSTARELOS K ET AL: "LIPOSOMES AS CARRIERS OF RADIONUCLIDES: FROM IMAGING TO THERAPY", JOURNAL OF LIPOSOME RESEARCH, MARCEL DEKKER, NEW YORK, US, vol. 9, no. 4, November 1999 (1999-11-01), pages 429 - 460, XP000878065, ISSN: 0898-2104 *
See also references of WO0053234A1 *
VIRGOLINI I ET AL: "INDIUM-111-DOTA-LANREOTIDE: BIODISTRIBUTION, SAFETY AND RADIATION ABSORBED DOSE IN TUMOR PATIENTS", JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE. NEW YORK, US, vol. 39, no. 11, November 1998 (1998-11-01), pages 1928 - 1936, XP001073903, ISSN: 0161-5505 *
ZWEIT J: "RADIONUCLIDES AND CARRIER MOLECULES FOR THERAPY", PHYSICS IN MEDICINE AND BIOLOGY, TAYLOR AND FRANCIS LTD. LONDON, GB, vol. 41, 1996, pages 1905 - 1914, XP001079428, ISSN: 0031-9155 *

Also Published As

Publication number Publication date
CA2366593A1 (fr) 2000-09-14
JP2002538225A (ja) 2002-11-12
WO2000053234A1 (fr) 2000-09-14
EP1165146A1 (fr) 2002-01-02

Similar Documents

Publication Publication Date Title
IL145839A0 (en) ESTROGEN RECEPTOR-β LIGANDS
EP0975803A4 (fr) Methode d'evaluation d'un cancer de la prostate
EP1146912A4 (fr) Procedes et agents destines a une radiotherapie amelioree
HRP20020422A2 (en) A method for chemoprevention of prostate cancer
PL354540A1 (en) Drugs for the treatment of malignant tumours
SI1176964T1 (sl) Uporaba et743 za zdravljenje raka
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
GB9930570D0 (en) Therapy
PT1231840E (pt) Agente celular antiangiogénico para terapia de cancro
HK1049962A1 (zh) 用於緩解腫瘤和抑制癌症的方法和製劑
EP1208232A4 (fr) Marqueurs du cancer de la prostate
EP1165146A4 (fr) Composes chelates metalliques radioactifs liposolubles destines au traitement de tumeurs
EP1189610A4 (fr) Methode et marqueurs de pronostic de l'efficacite d'agents anticancereux
HUP0200717A3 (en) Radioactive cisplatin in the treatment of cancer
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
AU3230300A (en) Bifurcated method for preventing breast ductal cancer
HUP0103557A3 (en) Use of an anthracycline derivative for the treatment of a liver tumor
GB9703633D0 (en) Cancer therapy
PL352681A1 (en) Preventive and therapeutic agents for cancer
EP1232176A4 (fr) Facteur suppresseur de tumeur
GB9906130D0 (en) Compounds for use in therapy
GB9922946D0 (en) Electromagnetic shielding
SI1157041T1 (sl) Protitelesa za terapijo in diagnozo raka
IL136778A0 (en) Reflex method for the detection of prostate cancer
GB9914971D0 (en) Treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 51/00 A

Ipc: 7A 61K 51/04 B

Ipc: 7C 07F 5/00 B

Ipc: 7A 61N 5/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030801

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071002